PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer

被引:3
|
作者
Wang, Jiaxi [1 ,2 ,3 ,4 ]
Peng, Yuanyuan [1 ]
Guo, Hejia [5 ]
Li, Cuiping [2 ,3 ,4 ,6 ]
机构
[1] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Periodontal & Oral Med, Nanning, Peoples R China
[2] Guangxi Key Lab Oral & Maxillofacial Rehabil & Re, Nanning, Peoples R China
[3] Guangxi Key Lab Oral & Maxillofacial Surg Dis Tre, Nanning, Peoples R China
[4] Guangxi Med Univ, Coll Stomatol, Guangxi Hlth Commiss Key Lab Prevent & Treatment, Guangxi Clin Res Ctr Craniofacial Deform, Nanning, Peoples R China
[5] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanning, Peoples R China
[6] Guangxi Med Univ, Coll Stomatol, Med Sci Res Ctr, Nanning, Peoples R China
关键词
cancer; polymorphism; PAI-1; meta-analysis; PLASMINOGEN-ACTIVATOR INHIBITOR-1; 4G/5G POLYMORPHISM; GENE POLYMORPHISMS; SUSCEPTIBILITY; EXPRESSION; SYSTEM; PROBABILITY; ANTIGEN; FALSE; UPA;
D O I
10.1177/15330338211037813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The plasminogen activator inhibitor-1 (PAI-1) was found in many types of tumor cells, which involved in tumorigenesis. Some studies investigated the associations between PAI-1 polymorphisms and various cancers, but the results were inconsistent. So this study did a meta-analysis to assess the strength of relationship between PAI-1 and cancer. Methods: Articles that meet the requirements were searched from PubMed, EMBASE, MEDLINE, Scopus, CNKI, Wanfang and SinoMed electronic databases before June 17th 2021. Stata version 11.2 was performed to merge the odds ratios (ORs) values and calculate 95% confidence intervals (CIs). Stratified analyses were assessed on the basis of types of cancer, ethnicity and source of the control group. Heterogeneity and sensitivity analysis were tested, and publication bias was also estimated. A meta-regression analysis was applied to explore sources of heterogeneity. The false-positive report probabilities (FPRP) and the Bayesian False Discovery Probability (BFDP) test were used to assess the credibility of statistically significant associations. Results: Ultimately, in this study, 33 eligible reports were included with 9550 cases and 10431 controls for the rs1799889 polymorphism, 5 reports with 2705 cases and 3168 controls for the rs2227631 polymorphism, and 4 reports with 2799 cases and 4011 controls for the rs2227667 polymorphism. The ORs and 95% CIs showed a statistically significant relationship between rs1799889 4G>5G polymorphism and cancer risk, especially in feminine cancer. The term refers to cancers that occur in the female reproductive system, such as ovarian, breast, endometrial and cervical cancer. Moreover, there was no association observed for the PAI-1 promoter A>G polymorphism (rs2227631 and rs2227667). In further subgroup analyses of 4G>5G polymorphism (rs1799889), an increased susceptibility to cancer was observed in Caucasians group and some types of cancer groups. Conclusions: This article comes to a conclusion that the rs1799889 polymorphism might help to increase the risk of cancer; moreover, the susceptibility to feminine cancer is more evident.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] The PAI-1 swing:: Microenvironment and cancer cell migration.
    Malo, Michel
    Charriere-Bertrand, Cecile
    Chettaoui, Chafika
    Fabre-Guillevin, Elizabeth
    Maquerlot, Francois
    Lackmy, Alexandra
    Vallee, Benoit
    Delaplace, Franck
    Barlovatz-Meimon, Georgia
    COMPTES RENDUS BIOLOGIES, 2006, 329 (12) : 919 - 927
  • [22] uPA and PAI-1: Clinically Validated Biomarkers in Breast Cancer
    Duffy, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 30 - 30
  • [23] PAI-1 genotype, PAI-1 level and risk of thrombotic complications after renal transplantation
    Green, FR
    Irish, AB
    Gray, D
    Morris, PJ
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 190 - 190
  • [24] Type 1 plasminogen activator inhibitor (PAI-1) and risk of colorectal cancer in the european prospective investigation into cancer (EPIC)-Italy cohort
    Iacoviello, L.
    Agnoli, C.
    De Curtis, A.
    Giurdanella, M. C.
    Krogh, V
    Mattiello, A.
    Matullo, G.
    Panico, S.
    Sacerdote, C.
    Tumino, R.
    Vineis, P.
    Donati, M. B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 93 - 93
  • [25] ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR -1 (PAI-1) IN CANCER STEM CELLS
    Irmak-Yazicioglu, M. B.
    Ergun, K.
    WORLD CANCER RESEARCH JOURNAL, 2022, 9
  • [26] Plasminogen-activator inhibitor-1 in (PAI-1) gastric cancer
    Tabuchi, Y
    Nakamura, T
    Miyamura, K
    Nakae, S
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 447 - 450
  • [27] Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility
    Oh, Jisu
    An, Hui Jeong
    Kim, Jung Oh
    Jun, Hak Hoon
    Kim, Woo Ram
    Kim, Eo Jin
    Oh, Doyeun
    Kim, Jong Woo
    Kim, Nam Keun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 15
  • [28] Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
    Wieder, V.
    Engel, J.
    Bauer, M.
    Kaufhold, S.
    Hanf, V.
    Uleer, C.
    Lantzsch, T.
    Peschel, S.
    John, J.
    Poehler, M.
    Weigert, E.
    Burrig, K-F.
    Buchmann, J.
    Kantelhardt, E.
    Thomssen, C.
    Vetter, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S297 - S297
  • [29] Mutated PAI-1 inhibits proliferative activity of lung cancer cells
    Chorostowska-Wynimko, Joanna
    Kedzior, Marta
    Struniawski, Radoslaw
    Gruber, Beata
    Anuszewska, Elzbieta
    Skrzypczak-Jankun, Ewa
    Jankun, Jerzy
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S609 - S609
  • [30] MAPPING OF PAI-1 TO A REGION OF ABNORMALITIES OF CHROMOSOME-7 IN CANCER
    WINQVIST, R
    KLINGER, K
    ALITALO, K
    DANO, K
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11): : 1812 - 1813